 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ALENDRONATE SODIUM increase or decrease the risk of[0m
[34mmyocardial infarction?[0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ALENDRONATE SODIUM increase or decrease the risk of myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ALENDRONATE SODIUM increase or decrease the risk of[0m
[32mmyocardial infarction?[0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ALENDRONATE SODIUM increase or decrease the risk of myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ALENDRONATE SODIUM increase or decrease the risk of myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"ALENDRONATE SODIUM"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: ALENDRONATE SODIUM: clinical_pharmacology: Long-term treatment of osteoporosis with alendronate sodium [0m[1;31m10[0m[31m mg/day [0m[1;31m([0m[31mfor up to five years[0m[1;31m)[0m[31m reduced urinary excretion of markers of bone [0m
[31mresorption, deoxypyridinoline and cross-linked N-telopeptides of type l collagen, by approximately [0m[1;31m50[0m[31m% and [0m[1;31m70[0m[31m%, respectively, to reach levels similar to those seen in healthy premenopausal women. [0m
[31mSimilar decreases were seen in patients in osteoporosis prevention studies who received alendronate sodium [0m[1;31m5[0m[31m mg/day. The decrease in the rate of bone resorption indicated by these markers was evident [0m
[31mas early as [0m[1;31m1[0m[31m month and at [0m[1;31m3[0m[31m to [0m[1;31m6[0m[31m months reached a plateau that was maintained for the entire duration of treatment with alendronate sodium. ALENDRONATE SODIUM: clinical_pharmacology: In osteoporosis [0m
[31mtreatment studies alendronate sodium [0m[1;31m10[0m[31m mg/day decreased the markers of bone formation, osteocalcin and bone specific alkaline phosphatase by approximately [0m[1;31m50[0m[31m%, and total serum alkaline phosphatase by[0m
[31mapproximately [0m[1;31m25[0m[31m to [0m[1;31m30[0m[31m% to reach a plateau after [0m[1;31m6[0m[31m to [0m[1;31m12[0m[31m months. In osteoporosis prevention studies alendronate sodium [0m[1;31m5[0m[31m mg/day decreased osteocalcin and total serum alkaline phosphatase by [0m
[31mapproximately [0m[1;31m40[0m[31m% and [0m[1;31m15[0m[31m%, respectively. Similar reductions in the rate of bone turnover were observed in postmenopausal women during one-year studies with once weekly alendronate sodium [0m[1;31m70[0m[31m mg for the[0m
[31mtreatment of osteoporosis and once weekly alendronate sodium [0m[1;31m35[0m[31m mg for the prevention of osteoporosis. These data indicate that the rate of bone turnover reached a new steady state, despite the [0m
[31mprogressive increase in the total amount of alendronate deposited within bone. ALENDRONATE SODIUM: clinical_pharmacology: As a result of inhibition of bone resorption, asymptomatic reductions in serum[0m
[31mcalcium and phosphate concentrations were also observed following treatment with alendronate sodium. In the long-term studies, reductions from baseline in serum calcium [0m[1;31m([0m[31mapproximately [0m[1;31m2[0m[31m%[0m[1;31m)[0m[31m and [0m
[31mphosphate [0m[1;31m([0m[31mapproximately [0m[1;31m4[0m[31m to [0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m were evident the first month after the initiation of alendronate sodium [0m[1;31m10[0m[31m mg. No further decreases in serum calcium were observed for the five-year duration of [0m
[31mtreatment; however, serum phosphate returned toward prestudy levels during years three through five. Similar reductions were observed with alendronate sodium [0m[1;31m5[0m[31m mg/day. In one-year studies with once [0m
[31mweekly alendronate sodium [0m[1;31m35[0m[31m and [0m[1;31m70[0m[31m mg, similar reductions were observed at [0m[1;31m6[0m[31m and [0m[1;31m12[0m[31m months. The reduction in serum phosphate may reflect not only the positive bone mineral balance due to alendronate [0m
[31msodium but also a decrease in renal phosphate reabsorption. ALENDRONATE SODIUM: clinical_pharmacology: Osteoporosis in Men Treatment of men with osteoporosis with alendronate sodium [0m[1;31m10[0m[31m mg/day for two [0m
[31myears reduced urinary excretion of cross-linked N-telopeptides of type I collagen by approximately [0m[1;31m60[0m[31m% and bone-specific alkaline phosphatase by approximately [0m[1;31m40[0m[31m%. Similar reductions were observed in [0m
[31ma one-year study in men with osteoporosis receiving once weekly alendronate sodium [0m[1;31m70[0m[31m mg. [0m[1;31m12.3[0m[31m Pharmacokinetics Absorption Relative to an intravenous [0m[1;31m([0m[31mIV[0m[1;31m)[0m[31m reference dose, the mean oral bioavailability[0m
[31mof alendronate in women was [0m[1;31m0.64[0m[31m% for doses ranging from [0m[1;31m5[0m[31m to [0m[1;31m70[0m[31m mg when administered after an overnight fast and two hours before a standardized breakfast. Oral bioavailability of the [0m[1;31m10[0m[31m mg tablet in[0m
[31mmen [0m[1;31m([0m[1;31m0.59[0m[31m%[0m[1;31m)[0m[31m was similar to that in women when administered after an overnight fast and [0m[1;31m2[0m[31m hours before breakfast. ALENDRONATE SODIUM: clinical_pharmacology: BINOSTO [0m[1;31m70[0m[31m mg effervescent tablet and [0m
[31malendronate sodium [0m[1;31m70[0m[31m mg tablet are bioequivalent. A study evaluating the effect of food on the bioavailability of BINOSTO was performed in [0m[1;31m119[0m[31m healthy women. Bioavailability was decreased [0m[1;31m([0m[31mby [0m
[31mapproximately [0m[1;31m50[0m[31m%[0m[1;31m)[0m[31m when [0m[1;31m70[0m[31m mg alendronate sodium was administered [0m[1;31m15[0m[31m minutes before a standardized breakfast, when compared to dosing [0m[1;31m4[0m[31m hours before eating. In studies of treatment and prevention of [0m
[31mosteoporosis, alendronate was effective when administered at least [0m[1;31m30[0m[31m minutes before breakfast. Bioavailability was negligible whether alendronate sodium was administered with or up to [0m[1;31m2[0m[31m hours after a[0m
[31mstandardized breakfast. Concomitant administration of alendronate with coffee or orange juice reduced bioavailability by approximately [0m[1;31m60[0m[31m%.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE SODIUM label[0m


[31mCONTENT: ALENDRONATE SODIUM: indications_and_usage: [0m[1;31m1[0m[31m INDICATIONS AND USAGE BINOSTO is a bisphosphonate indicated for: Treatment of osteoporosis in postmenopausal women [0m[1;31m([0m[31m [0m[1;31m1.1[0m[31m [0m[1;31m)[0m[31m Treatment to increase [0m
[31mbone mass in men with osteoporosis [0m[1;31m([0m[31m [0m[1;31m1.2[0m[31m [0m[1;31m)[0m[31m Limitation of use: Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after [0m[1;31m3[0m[31m to [0m[1;31m5[0m[31m years [0m
[31mof use [0m[1;31m([0m[31m [0m[1;31m1.3[0m[31m [0m[1;31m)[0m[31m [0m[1;31m1.1[0m[31m Treatment of Osteoporosis in Postmenopausal Women BINOSTO effervescent tablet [0m[1;31m70[0m[31m mg is indicated for the treatment of osteoporosis in postmenopausal women. For the treatment of [0m
[31mosteoporosis, alendronate sodium increases bone mass and reduces the incidence of fractures, including those of the hip and spine [0m[1;31m([0m[31mvertebral compression fractures[0m[1;31m)[0m[31m. [0m[1;31m[[0m[31mSee Clinical Studies [0m[1;31m([0m[1;31m14.1[0m[1;31m)[0m[31m .[0m[1;31m][0m[31m [0m[1;31m1[0m[31m. [0m
[31mALENDRONATE SODIUM: indications_and_usage: [0m[1;31m2[0m[31m Treatment to Increase Bone Mass in Men With Osteoporosis BINOSTO is indicated for treatment to increase bone mass in men with osteoporosis [0m[31m . [0m[1;31m1.3[0m[31m Important[0m
[31mLimitations of Use The optimal duration of use has not been determined. The safety and effectiveness of BINOSTO for the treatment of osteoporosis are based on clinical data of four years duration. All[0m
[31mpatients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. Patients at low-risk for fracture should be considered for drug discontinuation after [0m[1;31m3[0m[31m [0m
[31mto [0m[1;31m5[0m[31m years of use. Patients who discontinue therapy should have their risk for fracture re-evaluated periodically.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE SODIUM label[0m


[31mCONTENT: ALENDRONATE SODIUM: warnings_and_cautions: [0m[1;31m5[0m[31m WARNINGS AND PRECAUTIONS Upper Gastrointestinal Adverse Reactions can occur. Instruct patients to follow dosing instructions. Discontinue if new [0m
[31mor worsening symptoms occur. [0m[1;31m([0m[31m [0m[1;31m5.1[0m[31m [0m[1;31m)[0m[31m Hypocalcemia can worsen and must be corrected prior to use. [0m[1;31m([0m[31m [0m[1;31m5.2[0m[31m [0m[1;31m)[0m[31m Severe Bone, Joint, Muscle Pain may occur. Discontinue use if severe symptoms develop. [0m[1;31m([0m[31m [0m[1;31m5.3[0m[31m [0m[1;31m)[0m[31m [0m
[31mOsteonecrosis of the Jaw has been reported. [0m[1;31m([0m[31m [0m[1;31m5.4[0m[31m [0m[1;31m)[0m[31m Atypical Femur Fractures have been reported. Patients with new thigh or groin pain should be evaluated to rule out a femoral fracture. [0m[1;31m([0m[31m [0m[1;31m5.5[0m[31m [0m[1;31m)[0m[31m [0m
[31mSodium Content: Each tablet contains [0m[1;31m603[0m[31m mg sodium, equivalent to [0m[1;31m1532[0m[31m mg NaCl. Use caution in patients on sodium restriction. [0m[1;31m([0m[31m [0m[1;31m5.7[0m[31m [0m[1;31m)[0m[31m [0m[1;31m5[0m[31m. ALENDRONATE SODIUM: warnings_and_cautions: [0m[1;31m1[0m[31m Upper [0m
[31mGastrointestinal Adverse Reactions BINOSTO, like other bisphosphonates administered orally, may cause local irritation of the upper gastrointestinal mucosa. Because of these possible irritant effects [0m
[31mand a potential for worsening of the underlying disease, caution should be used when BINOSTO is given to patients with active upper gastrointestinal problems [0m[1;31m([0m[31msuch as known Barrett's esophagus, [0m
[31mdysphagia, other esophageal diseases, gastritis, duodenitis, or ulcers[0m[1;31m)[0m[31m. Esophageal adverse experiences, such as esophagitis, esophageal ulcers and esophageal erosions, occasionally with bleeding and [0m
[31mrarely followed by esophageal stricture or perforation, have been reported in patients receiving treatment with oral bisphosphonates including alendronate sodium. In some cases these have been severe [0m
[31mand required hospitalization. ALENDRONATE SODIUM: warnings_and_cautions: Physicians should therefore be alert to any signs or symptoms signaling a possible esophageal reaction and patients should be [0m
[31minstructed to discontinue BINOSTO and seek medical attention if they develop dysphagia, odynophagia, retrosternal pain or new or worsening heartburn. The risk of severe esophageal adverse experiences [0m
[31mappears to be greater in patients who lie down after taking oral bisphosphonates including alendronate sodium, and/or who continue to take oral bisphosphonates including alendronate sodium after [0m
[31mdeveloping symptoms suggestive of esophageal irritation. Therefore, it is very important that the full dosing instructions are provided to, and understood by, the patient [0m[31m . In patients who cannot [0m
[31mcomply with dosing instructions due to mental disability, therapy with BINOSTO should be used under appropriate supervision.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE SODIUM label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32m DO-NOT-KNOW[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ALENDRONATE SODIUM increase or decrease the risk of myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ALENDRONATE SODIUM"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does ALENDRONATE SODIUM increase or decrease the [0m
[31mrisk of myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ALENDRONATE SODIUM increase or decrease the risk of myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ALENDRONATE SODIUM increase or decrease the risk of[0m
[32mmyocardial infarction?[0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ALENDRONATE SODIUM increase or decrease the risk of myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ALENDRONATE SODIUM increase or decrease the risk of myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ALENDRONATE SODIUM"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: ALENDRONATE SODIUM: clinical_pharmacology: Long-term treatment of osteoporosis with alendronate sodium [0m[1;31m10[0m[31m mg/day [0m[1;31m([0m[31mfor up to five years[0m[1;31m)[0m[31m reduced urinary excretion of markers of bone [0m
[31mresorption, deoxypyridinoline and cross-linked N-telopeptides of type l collagen, by approximately [0m[1;31m50[0m[31m% and [0m[1;31m70[0m[31m%, respectively, to reach levels similar to those seen in healthy premenopausal women. [0m
[31mSimilar decreases were seen in patients in osteoporosis prevention studies who received alendronate sodium [0m[1;31m5[0m[31m mg/day. The decrease in the rate of bone resorption indicated by these markers was evident [0m
[31mas early as [0m[1;31m1[0m[31m month and at [0m[1;31m3[0m[31m to [0m[1;31m6[0m[31m months reached a plateau that was maintained for the entire duration of treatment with alendronate sodium. ALENDRONATE SODIUM: clinical_pharmacology: In osteoporosis [0m
[31mtreatment studies alendronate sodium [0m[1;31m10[0m[31m mg/day decreased the markers of bone formation, osteocalcin and bone specific alkaline phosphatase by approximately [0m[1;31m50[0m[31m%, and total serum alkaline phosphatase by[0m
[31mapproximately [0m[1;31m25[0m[31m to [0m[1;31m30[0m[31m% to reach a plateau after [0m[1;31m6[0m[31m to [0m[1;31m12[0m[31m months. In osteoporosis prevention studies alendronate sodium [0m[1;31m5[0m[31m mg/day decreased osteocalcin and total serum alkaline phosphatase by [0m
[31mapproximately [0m[1;31m40[0m[31m% and [0m[1;31m15[0m[31m%, respectively. Similar reductions in the rate of bone turnover were observed in postmenopausal women during one-year studies with once weekly alendronate sodium [0m[1;31m70[0m[31m mg for the[0m
[31mtreatment of osteoporosis and once weekly alendronate sodium [0m[1;31m35[0m[31m mg for the prevention of osteoporosis. These data indicate that the rate of bone turnover reached a new steady state, despite the [0m
[31mprogressive increase in the total amount of alendronate deposited within bone. ALENDRONATE SODIUM: clinical_pharmacology: As a result of inhibition of bone resorption, asymptomatic reductions in serum[0m
[31mcalcium and phosphate concentrations were also observed following treatment with alendronate sodium. In the long-term studies, reductions from baseline in serum calcium [0m[1;31m([0m[31mapproximately [0m[1;31m2[0m[31m%[0m[1;31m)[0m[31m and [0m
[31mphosphate [0m[1;31m([0m[31mapproximately [0m[1;31m4[0m[31m to [0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m were evident the first month after the initiation of alendronate sodium [0m[1;31m10[0m[31m mg. No further decreases in serum calcium were observed for the five-year duration of [0m
[31mtreatment; however, serum phosphate returned toward prestudy levels during years three through five. Similar reductions were observed with alendronate sodium [0m[1;31m5[0m[31m mg/day. In one-year studies with once [0m
[31mweekly alendronate sodium [0m[1;31m35[0m[31m and [0m[1;31m70[0m[31m mg, similar reductions were observed at [0m[1;31m6[0m[31m and [0m[1;31m12[0m[31m months. The reduction in serum phosphate may reflect not only the positive bone mineral balance due to alendronate [0m
[31msodium but also a decrease in renal phosphate reabsorption. ALENDRONATE SODIUM: clinical_pharmacology: Osteoporosis in Men Treatment of men with osteoporosis with alendronate sodium [0m[1;31m10[0m[31m mg/day for two [0m
[31myears reduced urinary excretion of cross-linked N-telopeptides of type I collagen by approximately [0m[1;31m60[0m[31m% and bone-specific alkaline phosphatase by approximately [0m[1;31m40[0m[31m%. Similar reductions were observed in [0m
[31ma one-year study in men with osteoporosis receiving once weekly alendronate sodium [0m[1;31m70[0m[31m mg. [0m[1;31m12.3[0m[31m Pharmacokinetics Absorption Relative to an intravenous [0m[1;31m([0m[31mIV[0m[1;31m)[0m[31m reference dose, the mean oral bioavailability[0m
[31mof alendronate in women was [0m[1;31m0.64[0m[31m% for doses ranging from [0m[1;31m5[0m[31m to [0m[1;31m70[0m[31m mg when administered after an overnight fast and two hours before a standardized breakfast. Oral bioavailability of the [0m[1;31m10[0m[31m mg tablet in[0m
[31mmen [0m[1;31m([0m[1;31m0.59[0m[31m%[0m[1;31m)[0m[31m was similar to that in women when administered after an overnight fast and [0m[1;31m2[0m[31m hours before breakfast. ALENDRONATE SODIUM: clinical_pharmacology: BINOSTO [0m[1;31m70[0m[31m mg effervescent tablet and [0m
[31malendronate sodium [0m[1;31m70[0m[31m mg tablet are bioequivalent. A study evaluating the effect of food on the bioavailability of BINOSTO was performed in [0m[1;31m119[0m[31m healthy women. Bioavailability was decreased [0m[1;31m([0m[31mby [0m
[31mapproximately [0m[1;31m50[0m[31m%[0m[1;31m)[0m[31m when [0m[1;31m70[0m[31m mg alendronate sodium was administered [0m[1;31m15[0m[31m minutes before a standardized breakfast, when compared to dosing [0m[1;31m4[0m[31m hours before eating. In studies of treatment and prevention of [0m
[31mosteoporosis, alendronate was effective when administered at least [0m[1;31m30[0m[31m minutes before breakfast. Bioavailability was negligible whether alendronate sodium was administered with or up to [0m[1;31m2[0m[31m hours after a[0m
[31mstandardized breakfast. Concomitant administration of alendronate with coffee or orange juice reduced bioavailability by approximately [0m[1;31m60[0m[31m%.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE SODIUM label[0m


[31mCONTENT: ALENDRONATE SODIUM: indications_and_usage: [0m[1;31m1[0m[31m INDICATIONS AND USAGE BINOSTO is a bisphosphonate indicated for: Treatment of osteoporosis in postmenopausal women [0m[1;31m([0m[31m [0m[1;31m1.1[0m[31m [0m[1;31m)[0m[31m Treatment to increase [0m
[31mbone mass in men with osteoporosis [0m[1;31m([0m[31m [0m[1;31m1.2[0m[31m [0m[1;31m)[0m[31m Limitation of use: Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after [0m[1;31m3[0m[31m to [0m[1;31m5[0m[31m years [0m
[31mof use [0m[1;31m([0m[31m [0m[1;31m1.3[0m[31m [0m[1;31m)[0m[31m [0m[1;31m1.1[0m[31m Treatment of Osteoporosis in Postmenopausal Women BINOSTO effervescent tablet [0m[1;31m70[0m[31m mg is indicated for the treatment of osteoporosis in postmenopausal women. For the treatment of [0m
[31mosteoporosis, alendronate sodium increases bone mass and reduces the incidence of fractures, including those of the hip and spine [0m[1;31m([0m[31mvertebral compression fractures[0m[1;31m)[0m[31m. [0m[1;31m[[0m[31mSee Clinical Studies [0m[1;31m([0m[1;31m14.1[0m[1;31m)[0m[31m .[0m[1;31m][0m[31m [0m[1;31m1[0m[31m. [0m
[31mALENDRONATE SODIUM: indications_and_usage: [0m[1;31m2[0m[31m Treatment to Increase Bone Mass in Men With Osteoporosis BINOSTO is indicated for treatment to increase bone mass in men with osteoporosis [0m[31m . [0m[1;31m1.3[0m[31m Important[0m
[31mLimitations of Use The optimal duration of use has not been determined. The safety and effectiveness of BINOSTO for the treatment of osteoporosis are based on clinical data of four years duration. All[0m
[31mpatients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. Patients at low-risk for fracture should be considered for drug discontinuation after [0m[1;31m3[0m[31m [0m
[31mto [0m[1;31m5[0m[31m years of use. Patients who discontinue therapy should have their risk for fracture re-evaluated periodically.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE SODIUM label[0m


[31mCONTENT: ALENDRONATE SODIUM: warnings_and_cautions: [0m[1;31m5[0m[31m WARNINGS AND PRECAUTIONS Upper Gastrointestinal Adverse Reactions can occur. Instruct patients to follow dosing instructions. Discontinue if new [0m
[31mor worsening symptoms occur. [0m[1;31m([0m[31m [0m[1;31m5.1[0m[31m [0m[1;31m)[0m[31m Hypocalcemia can worsen and must be corrected prior to use. [0m[1;31m([0m[31m [0m[1;31m5.2[0m[31m [0m[1;31m)[0m[31m Severe Bone, Joint, Muscle Pain may occur. Discontinue use if severe symptoms develop. [0m[1;31m([0m[31m [0m[1;31m5.3[0m[31m [0m[1;31m)[0m[31m [0m
[31mOsteonecrosis of the Jaw has been reported. [0m[1;31m([0m[31m [0m[1;31m5.4[0m[31m [0m[1;31m)[0m[31m Atypical Femur Fractures have been reported. Patients with new thigh or groin pain should be evaluated to rule out a femoral fracture. [0m[1;31m([0m[31m [0m[1;31m5.5[0m[31m [0m[1;31m)[0m[31m [0m
[31mSodium Content: Each tablet contains [0m[1;31m603[0m[31m mg sodium, equivalent to [0m[1;31m1532[0m[31m mg NaCl. Use caution in patients on sodium restriction. [0m[1;31m([0m[31m [0m[1;31m5.7[0m[31m [0m[1;31m)[0m[31m [0m[1;31m5[0m[31m. ALENDRONATE SODIUM: warnings_and_cautions: [0m[1;31m1[0m[31m Upper [0m
[31mGastrointestinal Adverse Reactions BINOSTO, like other bisphosphonates administered orally, may cause local irritation of the upper gastrointestinal mucosa. Because of these possible irritant effects [0m
[31mand a potential for worsening of the underlying disease, caution should be used when BINOSTO is given to patients with active upper gastrointestinal problems [0m[1;31m([0m[31msuch as known Barrett's esophagus, [0m
[31mdysphagia, other esophageal diseases, gastritis, duodenitis, or ulcers[0m[1;31m)[0m[31m. Esophageal adverse experiences, such as esophagitis, esophageal ulcers and esophageal erosions, occasionally with bleeding and [0m
[31mrarely followed by esophageal stricture or perforation, have been reported in patients receiving treatment with oral bisphosphonates including alendronate sodium. In some cases these have been severe [0m
[31mand required hospitalization. ALENDRONATE SODIUM: warnings_and_cautions: Physicians should therefore be alert to any signs or symptoms signaling a possible esophageal reaction and patients should be [0m
[31minstructed to discontinue BINOSTO and seek medical attention if they develop dysphagia, odynophagia, retrosternal pain or new or worsening heartburn. The risk of severe esophageal adverse experiences [0m
[31mappears to be greater in patients who lie down after taking oral bisphosphonates including alendronate sodium, and/or who continue to take oral bisphosphonates including alendronate sodium after [0m
[31mdeveloping symptoms suggestive of esophageal irritation. Therefore, it is very important that the full dosing instructions are provided to, and understood by, the patient [0m[31m . In patients who cannot [0m
[31mcomply with dosing instructions due to mental disability, therapy with BINOSTO should be used under appropriate supervision.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE SODIUM label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ALENDRONATE SODIUM increase or decrease the risk of myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ALENDRONATE SODIUM increase or decrease the risk of[0m
[32mmyocardial infarction?[0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ALENDRONATE SODIUM increase or decrease the risk of myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ALENDRONATE SODIUM increase or decrease the risk of myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ALENDRONATE SODIUM"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does ALENDRONATE SODIUM increase or decrease the [0m
[31mrisk of myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ALENDRONATE SODIUM increase or decrease the risk of myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ALENDRONATE SODIUM increase or decrease the risk of[0m
[32mmyocardial infarction?[0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ALENDRONATE SODIUM increase or decrease the risk of myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ALENDRONATE SODIUM increase or decrease the risk of myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ALENDRONATE SODIUM"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: ALENDRONATE SODIUM: clinical_pharmacology: Long-term treatment of osteoporosis with alendronate sodium [0m[1;31m10[0m[31m mg/day [0m[1;31m([0m[31mfor up to five years[0m[1;31m)[0m[31m reduced urinary excretion of markers of bone [0m
[31mresorption, deoxypyridinoline and cross-linked N-telopeptides of type l collagen, by approximately [0m[1;31m50[0m[31m% and [0m[1;31m70[0m[31m%, respectively, to reach levels similar to those seen in healthy premenopausal women. [0m
[31mSimilar decreases were seen in patients in osteoporosis prevention studies who received alendronate sodium [0m[1;31m5[0m[31m mg/day. The decrease in the rate of bone resorption indicated by these markers was evident [0m
[31mas early as [0m[1;31m1[0m[31m month and at [0m[1;31m3[0m[31m to [0m[1;31m6[0m[31m months reached a plateau that was maintained for the entire duration of treatment with alendronate sodium. ALENDRONATE SODIUM: clinical_pharmacology: In osteoporosis [0m
[31mtreatment studies alendronate sodium [0m[1;31m10[0m[31m mg/day decreased the markers of bone formation, osteocalcin and bone specific alkaline phosphatase by approximately [0m[1;31m50[0m[31m%, and total serum alkaline phosphatase by[0m
[31mapproximately [0m[1;31m25[0m[31m to [0m[1;31m30[0m[31m% to reach a plateau after [0m[1;31m6[0m[31m to [0m[1;31m12[0m[31m months. In osteoporosis prevention studies alendronate sodium [0m[1;31m5[0m[31m mg/day decreased osteocalcin and total serum alkaline phosphatase by [0m
[31mapproximately [0m[1;31m40[0m[31m% and [0m[1;31m15[0m[31m%, respectively. Similar reductions in the rate of bone turnover were observed in postmenopausal women during one-year studies with once weekly alendronate sodium [0m[1;31m70[0m[31m mg for the[0m
[31mtreatment of osteoporosis and once weekly alendronate sodium [0m[1;31m35[0m[31m mg for the prevention of osteoporosis. These data indicate that the rate of bone turnover reached a new steady state, despite the [0m
[31mprogressive increase in the total amount of alendronate deposited within bone. ALENDRONATE SODIUM: clinical_pharmacology: As a result of inhibition of bone resorption, asymptomatic reductions in serum[0m
[31mcalcium and phosphate concentrations were also observed following treatment with alendronate sodium. In the long-term studies, reductions from baseline in serum calcium [0m[1;31m([0m[31mapproximately [0m[1;31m2[0m[31m%[0m[1;31m)[0m[31m and [0m
[31mphosphate [0m[1;31m([0m[31mapproximately [0m[1;31m4[0m[31m to [0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m were evident the first month after the initiation of alendronate sodium [0m[1;31m10[0m[31m mg. No further decreases in serum calcium were observed for the five-year duration of [0m
[31mtreatment; however, serum phosphate returned toward prestudy levels during years three through five. Similar reductions were observed with alendronate sodium [0m[1;31m5[0m[31m mg/day. In one-year studies with once [0m
[31mweekly alendronate sodium [0m[1;31m35[0m[31m and [0m[1;31m70[0m[31m mg, similar reductions were observed at [0m[1;31m6[0m[31m and [0m[1;31m12[0m[31m months. The reduction in serum phosphate may reflect not only the positive bone mineral balance due to alendronate [0m
[31msodium but also a decrease in renal phosphate reabsorption. ALENDRONATE SODIUM: clinical_pharmacology: Osteoporosis in Men Treatment of men with osteoporosis with alendronate sodium [0m[1;31m10[0m[31m mg/day for two [0m
[31myears reduced urinary excretion of cross-linked N-telopeptides of type I collagen by approximately [0m[1;31m60[0m[31m% and bone-specific alkaline phosphatase by approximately [0m[1;31m40[0m[31m%. Similar reductions were observed in [0m
[31ma one-year study in men with osteoporosis receiving once weekly alendronate sodium [0m[1;31m70[0m[31m mg. [0m[1;31m12.3[0m[31m Pharmacokinetics Absorption Relative to an intravenous [0m[1;31m([0m[31mIV[0m[1;31m)[0m[31m reference dose, the mean oral bioavailability[0m
[31mof alendronate in women was [0m[1;31m0.64[0m[31m% for doses ranging from [0m[1;31m5[0m[31m to [0m[1;31m70[0m[31m mg when administered after an overnight fast and two hours before a standardized breakfast. Oral bioavailability of the [0m[1;31m10[0m[31m mg tablet in[0m
[31mmen [0m[1;31m([0m[1;31m0.59[0m[31m%[0m[1;31m)[0m[31m was similar to that in women when administered after an overnight fast and [0m[1;31m2[0m[31m hours before breakfast. ALENDRONATE SODIUM: clinical_pharmacology: BINOSTO [0m[1;31m70[0m[31m mg effervescent tablet and [0m
[31malendronate sodium [0m[1;31m70[0m[31m mg tablet are bioequivalent. A study evaluating the effect of food on the bioavailability of BINOSTO was performed in [0m[1;31m119[0m[31m healthy women. Bioavailability was decreased [0m[1;31m([0m[31mby [0m
[31mapproximately [0m[1;31m50[0m[31m%[0m[1;31m)[0m[31m when [0m[1;31m70[0m[31m mg alendronate sodium was administered [0m[1;31m15[0m[31m minutes before a standardized breakfast, when compared to dosing [0m[1;31m4[0m[31m hours before eating. In studies of treatment and prevention of [0m
[31mosteoporosis, alendronate was effective when administered at least [0m[1;31m30[0m[31m minutes before breakfast. Bioavailability was negligible whether alendronate sodium was administered with or up to [0m[1;31m2[0m[31m hours after a[0m
[31mstandardized breakfast. Concomitant administration of alendronate with coffee or orange juice reduced bioavailability by approximately [0m[1;31m60[0m[31m%.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE SODIUM label[0m


[31mCONTENT: ALENDRONATE SODIUM: indications_and_usage: [0m[1;31m1[0m[31m INDICATIONS AND USAGE BINOSTO is a bisphosphonate indicated for: Treatment of osteoporosis in postmenopausal women [0m[1;31m([0m[31m [0m[1;31m1.1[0m[31m [0m[1;31m)[0m[31m Treatment to increase [0m
[31mbone mass in men with osteoporosis [0m[1;31m([0m[31m [0m[1;31m1.2[0m[31m [0m[1;31m)[0m[31m Limitation of use: Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after [0m[1;31m3[0m[31m to [0m[1;31m5[0m[31m years [0m
[31mof use [0m[1;31m([0m[31m [0m[1;31m1.3[0m[31m [0m[1;31m)[0m[31m [0m[1;31m1.1[0m[31m Treatment of Osteoporosis in Postmenopausal Women BINOSTO effervescent tablet [0m[1;31m70[0m[31m mg is indicated for the treatment of osteoporosis in postmenopausal women. For the treatment of [0m
[31mosteoporosis, alendronate sodium increases bone mass and reduces the incidence of fractures, including those of the hip and spine [0m[1;31m([0m[31mvertebral compression fractures[0m[1;31m)[0m[31m. [0m[1;31m[[0m[31mSee Clinical Studies [0m[1;31m([0m[1;31m14.1[0m[1;31m)[0m[31m .[0m[1;31m][0m[31m [0m[1;31m1[0m[31m. [0m
[31mALENDRONATE SODIUM: indications_and_usage: [0m[1;31m2[0m[31m Treatment to Increase Bone Mass in Men With Osteoporosis BINOSTO is indicated for treatment to increase bone mass in men with osteoporosis [0m[31m . [0m[1;31m1.3[0m[31m Important[0m
[31mLimitations of Use The optimal duration of use has not been determined. The safety and effectiveness of BINOSTO for the treatment of osteoporosis are based on clinical data of four years duration. All[0m
[31mpatients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. Patients at low-risk for fracture should be considered for drug discontinuation after [0m[1;31m3[0m[31m [0m
[31mto [0m[1;31m5[0m[31m years of use. Patients who discontinue therapy should have their risk for fracture re-evaluated periodically.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE SODIUM label[0m


[31mCONTENT: ALENDRONATE SODIUM: warnings_and_cautions: [0m[1;31m5[0m[31m WARNINGS AND PRECAUTIONS Upper Gastrointestinal Adverse Reactions can occur. Instruct patients to follow dosing instructions. Discontinue if new [0m
[31mor worsening symptoms occur. [0m[1;31m([0m[31m [0m[1;31m5.1[0m[31m [0m[1;31m)[0m[31m Hypocalcemia can worsen and must be corrected prior to use. [0m[1;31m([0m[31m [0m[1;31m5.2[0m[31m [0m[1;31m)[0m[31m Severe Bone, Joint, Muscle Pain may occur. Discontinue use if severe symptoms develop. [0m[1;31m([0m[31m [0m[1;31m5.3[0m[31m [0m[1;31m)[0m[31m [0m
[31mOsteonecrosis of the Jaw has been reported. [0m[1;31m([0m[31m [0m[1;31m5.4[0m[31m [0m[1;31m)[0m[31m Atypical Femur Fractures have been reported. Patients with new thigh or groin pain should be evaluated to rule out a femoral fracture. [0m[1;31m([0m[31m [0m[1;31m5.5[0m[31m [0m[1;31m)[0m[31m [0m
[31mSodium Content: Each tablet contains [0m[1;31m603[0m[31m mg sodium, equivalent to [0m[1;31m1532[0m[31m mg NaCl. Use caution in patients on sodium restriction. [0m[1;31m([0m[31m [0m[1;31m5.7[0m[31m [0m[1;31m)[0m[31m [0m[1;31m5[0m[31m. ALENDRONATE SODIUM: warnings_and_cautions: [0m[1;31m1[0m[31m Upper [0m
[31mGastrointestinal Adverse Reactions BINOSTO, like other bisphosphonates administered orally, may cause local irritation of the upper gastrointestinal mucosa. Because of these possible irritant effects [0m
[31mand a potential for worsening of the underlying disease, caution should be used when BINOSTO is given to patients with active upper gastrointestinal problems [0m[1;31m([0m[31msuch as known Barrett's esophagus, [0m
[31mdysphagia, other esophageal diseases, gastritis, duodenitis, or ulcers[0m[1;31m)[0m[31m. Esophageal adverse experiences, such as esophagitis, esophageal ulcers and esophageal erosions, occasionally with bleeding and [0m
[31mrarely followed by esophageal stricture or perforation, have been reported in patients receiving treatment with oral bisphosphonates including alendronate sodium. In some cases these have been severe [0m
[31mand required hospitalization. ALENDRONATE SODIUM: warnings_and_cautions: Physicians should therefore be alert to any signs or symptoms signaling a possible esophageal reaction and patients should be [0m
[31minstructed to discontinue BINOSTO and seek medical attention if they develop dysphagia, odynophagia, retrosternal pain or new or worsening heartburn. The risk of severe esophageal adverse experiences [0m
[31mappears to be greater in patients who lie down after taking oral bisphosphonates including alendronate sodium, and/or who continue to take oral bisphosphonates including alendronate sodium after [0m
[31mdeveloping symptoms suggestive of esophageal irritation. Therefore, it is very important that the full dosing instructions are provided to, and understood by, the patient [0m[31m . In patients who cannot [0m
[31mcomply with dosing instructions due to mental disability, therapy with BINOSTO should be used under appropriate supervision.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE SODIUM label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ALENDRONATE SODIUM increase or decrease the risk of myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ALENDRONATE SODIUM increase or decrease the risk of[0m
[32mmyocardial infarction?[0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ALENDRONATE SODIUM increase or decrease the risk of myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ALENDRONATE SODIUM increase or decrease the risk of myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ALENDRONATE SODIUM"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does ALENDRONATE SODIUM increase or decrease the [0m
[31mrisk of myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ALENDRONATE SODIUM increase or decrease the risk of myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ALENDRONATE SODIUM increase or decrease the risk of[0m
[32mmyocardial infarction?[0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ALENDRONATE SODIUM increase or decrease the risk of myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ALENDRONATE SODIUM increase or decrease the risk of myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ALENDRONATE SODIUM"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: ALENDRONATE SODIUM: clinical_pharmacology: Long-term treatment of osteoporosis with alendronate sodium [0m[1;31m10[0m[31m mg/day [0m[1;31m([0m[31mfor up to five years[0m[1;31m)[0m[31m reduced urinary excretion of markers of bone [0m
[31mresorption, deoxypyridinoline and cross-linked N-telopeptides of type l collagen, by approximately [0m[1;31m50[0m[31m% and [0m[1;31m70[0m[31m%, respectively, to reach levels similar to those seen in healthy premenopausal women. [0m
[31mSimilar decreases were seen in patients in osteoporosis prevention studies who received alendronate sodium [0m[1;31m5[0m[31m mg/day. The decrease in the rate of bone resorption indicated by these markers was evident [0m
[31mas early as [0m[1;31m1[0m[31m month and at [0m[1;31m3[0m[31m to [0m[1;31m6[0m[31m months reached a plateau that was maintained for the entire duration of treatment with alendronate sodium. ALENDRONATE SODIUM: clinical_pharmacology: In osteoporosis [0m
[31mtreatment studies alendronate sodium [0m[1;31m10[0m[31m mg/day decreased the markers of bone formation, osteocalcin and bone specific alkaline phosphatase by approximately [0m[1;31m50[0m[31m%, and total serum alkaline phosphatase by[0m
[31mapproximately [0m[1;31m25[0m[31m to [0m[1;31m30[0m[31m% to reach a plateau after [0m[1;31m6[0m[31m to [0m[1;31m12[0m[31m months. In osteoporosis prevention studies alendronate sodium [0m[1;31m5[0m[31m mg/day decreased osteocalcin and total serum alkaline phosphatase by [0m
[31mapproximately [0m[1;31m40[0m[31m% and [0m[1;31m15[0m[31m%, respectively. Similar reductions in the rate of bone turnover were observed in postmenopausal women during one-year studies with once weekly alendronate sodium [0m[1;31m70[0m[31m mg for the[0m
[31mtreatment of osteoporosis and once weekly alendronate sodium [0m[1;31m35[0m[31m mg for the prevention of osteoporosis. These data indicate that the rate of bone turnover reached a new steady state, despite the [0m
[31mprogressive increase in the total amount of alendronate deposited within bone. ALENDRONATE SODIUM: clinical_pharmacology: As a result of inhibition of bone resorption, asymptomatic reductions in serum[0m
[31mcalcium and phosphate concentrations were also observed following treatment with alendronate sodium. In the long-term studies, reductions from baseline in serum calcium [0m[1;31m([0m[31mapproximately [0m[1;31m2[0m[31m%[0m[1;31m)[0m[31m and [0m
[31mphosphate [0m[1;31m([0m[31mapproximately [0m[1;31m4[0m[31m to [0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m were evident the first month after the initiation of alendronate sodium [0m[1;31m10[0m[31m mg. No further decreases in serum calcium were observed for the five-year duration of [0m
[31mtreatment; however, serum phosphate returned toward prestudy levels during years three through five. Similar reductions were observed with alendronate sodium [0m[1;31m5[0m[31m mg/day. In one-year studies with once [0m
[31mweekly alendronate sodium [0m[1;31m35[0m[31m and [0m[1;31m70[0m[31m mg, similar reductions were observed at [0m[1;31m6[0m[31m and [0m[1;31m12[0m[31m months. The reduction in serum phosphate may reflect not only the positive bone mineral balance due to alendronate [0m
[31msodium but also a decrease in renal phosphate reabsorption. ALENDRONATE SODIUM: clinical_pharmacology: Osteoporosis in Men Treatment of men with osteoporosis with alendronate sodium [0m[1;31m10[0m[31m mg/day for two [0m
[31myears reduced urinary excretion of cross-linked N-telopeptides of type I collagen by approximately [0m[1;31m60[0m[31m% and bone-specific alkaline phosphatase by approximately [0m[1;31m40[0m[31m%. Similar reductions were observed in [0m
[31ma one-year study in men with osteoporosis receiving once weekly alendronate sodium [0m[1;31m70[0m[31m mg. [0m[1;31m12.3[0m[31m Pharmacokinetics Absorption Relative to an intravenous [0m[1;31m([0m[31mIV[0m[1;31m)[0m[31m reference dose, the mean oral bioavailability[0m
[31mof alendronate in women was [0m[1;31m0.64[0m[31m% for doses ranging from [0m[1;31m5[0m[31m to [0m[1;31m70[0m[31m mg when administered after an overnight fast and two hours before a standardized breakfast. Oral bioavailability of the [0m[1;31m10[0m[31m mg tablet in[0m
[31mmen [0m[1;31m([0m[1;31m0.59[0m[31m%[0m[1;31m)[0m[31m was similar to that in women when administered after an overnight fast and [0m[1;31m2[0m[31m hours before breakfast. ALENDRONATE SODIUM: clinical_pharmacology: BINOSTO [0m[1;31m70[0m[31m mg effervescent tablet and [0m
[31malendronate sodium [0m[1;31m70[0m[31m mg tablet are bioequivalent. A study evaluating the effect of food on the bioavailability of BINOSTO was performed in [0m[1;31m119[0m[31m healthy women. Bioavailability was decreased [0m[1;31m([0m[31mby [0m
[31mapproximately [0m[1;31m50[0m[31m%[0m[1;31m)[0m[31m when [0m[1;31m70[0m[31m mg alendronate sodium was administered [0m[1;31m15[0m[31m minutes before a standardized breakfast, when compared to dosing [0m[1;31m4[0m[31m hours before eating. In studies of treatment and prevention of [0m
[31mosteoporosis, alendronate was effective when administered at least [0m[1;31m30[0m[31m minutes before breakfast. Bioavailability was negligible whether alendronate sodium was administered with or up to [0m[1;31m2[0m[31m hours after a[0m
[31mstandardized breakfast. Concomitant administration of alendronate with coffee or orange juice reduced bioavailability by approximately [0m[1;31m60[0m[31m%.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE SODIUM label[0m


[31mCONTENT: ALENDRONATE SODIUM: indications_and_usage: [0m[1;31m1[0m[31m INDICATIONS AND USAGE BINOSTO is a bisphosphonate indicated for: Treatment of osteoporosis in postmenopausal women [0m[1;31m([0m[31m [0m[1;31m1.1[0m[31m [0m[1;31m)[0m[31m Treatment to increase [0m
[31mbone mass in men with osteoporosis [0m[1;31m([0m[31m [0m[1;31m1.2[0m[31m [0m[1;31m)[0m[31m Limitation of use: Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after [0m[1;31m3[0m[31m to [0m[1;31m5[0m[31m years [0m
[31mof use [0m[1;31m([0m[31m [0m[1;31m1.3[0m[31m [0m[1;31m)[0m[31m [0m[1;31m1.1[0m[31m Treatment of Osteoporosis in Postmenopausal Women BINOSTO effervescent tablet [0m[1;31m70[0m[31m mg is indicated for the treatment of osteoporosis in postmenopausal women. For the treatment of [0m
[31mosteoporosis, alendronate sodium increases bone mass and reduces the incidence of fractures, including those of the hip and spine [0m[1;31m([0m[31mvertebral compression fractures[0m[1;31m)[0m[31m. [0m[1;31m[[0m[31mSee Clinical Studies [0m[1;31m([0m[1;31m14.1[0m[1;31m)[0m[31m .[0m[1;31m][0m[31m [0m[1;31m1[0m[31m. [0m
[31mALENDRONATE SODIUM: indications_and_usage: [0m[1;31m2[0m[31m Treatment to Increase Bone Mass in Men With Osteoporosis BINOSTO is indicated for treatment to increase bone mass in men with osteoporosis [0m[31m . [0m[1;31m1.3[0m[31m Important[0m
[31mLimitations of Use The optimal duration of use has not been determined. The safety and effectiveness of BINOSTO for the treatment of osteoporosis are based on clinical data of four years duration. All[0m
[31mpatients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. Patients at low-risk for fracture should be considered for drug discontinuation after [0m[1;31m3[0m[31m [0m
[31mto [0m[1;31m5[0m[31m years of use. Patients who discontinue therapy should have their risk for fracture re-evaluated periodically.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE SODIUM label[0m


[31mCONTENT: ALENDRONATE SODIUM: warnings_and_cautions: [0m[1;31m5[0m[31m WARNINGS AND PRECAUTIONS Upper Gastrointestinal Adverse Reactions can occur. Instruct patients to follow dosing instructions. Discontinue if new [0m
[31mor worsening symptoms occur. [0m[1;31m([0m[31m [0m[1;31m5.1[0m[31m [0m[1;31m)[0m[31m Hypocalcemia can worsen and must be corrected prior to use. [0m[1;31m([0m[31m [0m[1;31m5.2[0m[31m [0m[1;31m)[0m[31m Severe Bone, Joint, Muscle Pain may occur. Discontinue use if severe symptoms develop. [0m[1;31m([0m[31m [0m[1;31m5.3[0m[31m [0m[1;31m)[0m[31m [0m
[31mOsteonecrosis of the Jaw has been reported. [0m[1;31m([0m[31m [0m[1;31m5.4[0m[31m [0m[1;31m)[0m[31m Atypical Femur Fractures have been reported. Patients with new thigh or groin pain should be evaluated to rule out a femoral fracture. [0m[1;31m([0m[31m [0m[1;31m5.5[0m[31m [0m[1;31m)[0m[31m [0m
[31mSodium Content: Each tablet contains [0m[1;31m603[0m[31m mg sodium, equivalent to [0m[1;31m1532[0m[31m mg NaCl. Use caution in patients on sodium restriction. [0m[1;31m([0m[31m [0m[1;31m5.7[0m[31m [0m[1;31m)[0m[31m [0m[1;31m5[0m[31m. ALENDRONATE SODIUM: warnings_and_cautions: [0m[1;31m1[0m[31m Upper [0m
[31mGastrointestinal Adverse Reactions BINOSTO, like other bisphosphonates administered orally, may cause local irritation of the upper gastrointestinal mucosa. Because of these possible irritant effects [0m
[31mand a potential for worsening of the underlying disease, caution should be used when BINOSTO is given to patients with active upper gastrointestinal problems [0m[1;31m([0m[31msuch as known Barrett's esophagus, [0m
[31mdysphagia, other esophageal diseases, gastritis, duodenitis, or ulcers[0m[1;31m)[0m[31m. Esophageal adverse experiences, such as esophagitis, esophageal ulcers and esophageal erosions, occasionally with bleeding and [0m
[31mrarely followed by esophageal stricture or perforation, have been reported in patients receiving treatment with oral bisphosphonates including alendronate sodium. In some cases these have been severe [0m
[31mand required hospitalization. ALENDRONATE SODIUM: warnings_and_cautions: Physicians should therefore be alert to any signs or symptoms signaling a possible esophageal reaction and patients should be [0m
[31minstructed to discontinue BINOSTO and seek medical attention if they develop dysphagia, odynophagia, retrosternal pain or new or worsening heartburn. The risk of severe esophageal adverse experiences [0m
[31mappears to be greater in patients who lie down after taking oral bisphosphonates including alendronate sodium, and/or who continue to take oral bisphosphonates including alendronate sodium after [0m
[31mdeveloping symptoms suggestive of esophageal irritation. Therefore, it is very important that the full dosing instructions are provided to, and understood by, the patient [0m[31m . In patients who cannot [0m
[31mcomply with dosing instructions due to mental disability, therapy with BINOSTO should be used under appropriate supervision.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE SODIUM label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ALENDRONATE SODIUM increase or decrease the risk of myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ALENDRONATE SODIUM increase or decrease the risk of[0m
[32mmyocardial infarction?[0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ALENDRONATE SODIUM increase or decrease the risk of myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ALENDRONATE SODIUM increase or decrease the risk of myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ALENDRONATE SODIUM"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does ALENDRONATE SODIUM increase or decrease the [0m
[31mrisk of myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ALENDRONATE SODIUM increase or decrease the risk of myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ALENDRONATE SODIUM increase or decrease the risk of[0m
[32mmyocardial infarction?[0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ALENDRONATE SODIUM increase or decrease the risk of myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ALENDRONATE SODIUM increase or decrease the risk of myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ALENDRONATE SODIUM"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: ALENDRONATE SODIUM: clinical_pharmacology: Long-term treatment of osteoporosis with alendronate sodium [0m[1;31m10[0m[31m mg/day [0m[1;31m([0m[31mfor up to five years[0m[1;31m)[0m[31m reduced urinary excretion of markers of bone [0m
[31mresorption, deoxypyridinoline and cross-linked N-telopeptides of type l collagen, by approximately [0m[1;31m50[0m[31m% and [0m[1;31m70[0m[31m%, respectively, to reach levels similar to those seen in healthy premenopausal women. [0m
[31mSimilar decreases were seen in patients in osteoporosis prevention studies who received alendronate sodium [0m[1;31m5[0m[31m mg/day. The decrease in the rate of bone resorption indicated by these markers was evident [0m
[31mas early as [0m[1;31m1[0m[31m month and at [0m[1;31m3[0m[31m to [0m[1;31m6[0m[31m months reached a plateau that was maintained for the entire duration of treatment with alendronate sodium. ALENDRONATE SODIUM: clinical_pharmacology: In osteoporosis [0m
[31mtreatment studies alendronate sodium [0m[1;31m10[0m[31m mg/day decreased the markers of bone formation, osteocalcin and bone specific alkaline phosphatase by approximately [0m[1;31m50[0m[31m%, and total serum alkaline phosphatase by[0m
[31mapproximately [0m[1;31m25[0m[31m to [0m[1;31m30[0m[31m% to reach a plateau after [0m[1;31m6[0m[31m to [0m[1;31m12[0m[31m months. In osteoporosis prevention studies alendronate sodium [0m[1;31m5[0m[31m mg/day decreased osteocalcin and total serum alkaline phosphatase by [0m
[31mapproximately [0m[1;31m40[0m[31m% and [0m[1;31m15[0m[31m%, respectively. Similar reductions in the rate of bone turnover were observed in postmenopausal women during one-year studies with once weekly alendronate sodium [0m[1;31m70[0m[31m mg for the[0m
[31mtreatment of osteoporosis and once weekly alendronate sodium [0m[1;31m35[0m[31m mg for the prevention of osteoporosis. These data indicate that the rate of bone turnover reached a new steady state, despite the [0m
[31mprogressive increase in the total amount of alendronate deposited within bone. ALENDRONATE SODIUM: clinical_pharmacology: As a result of inhibition of bone resorption, asymptomatic reductions in serum[0m
[31mcalcium and phosphate concentrations were also observed following treatment with alendronate sodium. In the long-term studies, reductions from baseline in serum calcium [0m[1;31m([0m[31mapproximately [0m[1;31m2[0m[31m%[0m[1;31m)[0m[31m and [0m
[31mphosphate [0m[1;31m([0m[31mapproximately [0m[1;31m4[0m[31m to [0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m were evident the first month after the initiation of alendronate sodium [0m[1;31m10[0m[31m mg. No further decreases in serum calcium were observed for the five-year duration of [0m
[31mtreatment; however, serum phosphate returned toward prestudy levels during years three through five. Similar reductions were observed with alendronate sodium [0m[1;31m5[0m[31m mg/day. In one-year studies with once [0m
[31mweekly alendronate sodium [0m[1;31m35[0m[31m and [0m[1;31m70[0m[31m mg, similar reductions were observed at [0m[1;31m6[0m[31m and [0m[1;31m12[0m[31m months. The reduction in serum phosphate may reflect not only the positive bone mineral balance due to alendronate [0m
[31msodium but also a decrease in renal phosphate reabsorption. ALENDRONATE SODIUM: clinical_pharmacology: Osteoporosis in Men Treatment of men with osteoporosis with alendronate sodium [0m[1;31m10[0m[31m mg/day for two [0m
[31myears reduced urinary excretion of cross-linked N-telopeptides of type I collagen by approximately [0m[1;31m60[0m[31m% and bone-specific alkaline phosphatase by approximately [0m[1;31m40[0m[31m%. Similar reductions were observed in [0m
[31ma one-year study in men with osteoporosis receiving once weekly alendronate sodium [0m[1;31m70[0m[31m mg. [0m[1;31m12.3[0m[31m Pharmacokinetics Absorption Relative to an intravenous [0m[1;31m([0m[31mIV[0m[1;31m)[0m[31m reference dose, the mean oral bioavailability[0m
[31mof alendronate in women was [0m[1;31m0.64[0m[31m% for doses ranging from [0m[1;31m5[0m[31m to [0m[1;31m70[0m[31m mg when administered after an overnight fast and two hours before a standardized breakfast. Oral bioavailability of the [0m[1;31m10[0m[31m mg tablet in[0m
[31mmen [0m[1;31m([0m[1;31m0.59[0m[31m%[0m[1;31m)[0m[31m was similar to that in women when administered after an overnight fast and [0m[1;31m2[0m[31m hours before breakfast. ALENDRONATE SODIUM: clinical_pharmacology: BINOSTO [0m[1;31m70[0m[31m mg effervescent tablet and [0m
[31malendronate sodium [0m[1;31m70[0m[31m mg tablet are bioequivalent. A study evaluating the effect of food on the bioavailability of BINOSTO was performed in [0m[1;31m119[0m[31m healthy women. Bioavailability was decreased [0m[1;31m([0m[31mby [0m
[31mapproximately [0m[1;31m50[0m[31m%[0m[1;31m)[0m[31m when [0m[1;31m70[0m[31m mg alendronate sodium was administered [0m[1;31m15[0m[31m minutes before a standardized breakfast, when compared to dosing [0m[1;31m4[0m[31m hours before eating. In studies of treatment and prevention of [0m
[31mosteoporosis, alendronate was effective when administered at least [0m[1;31m30[0m[31m minutes before breakfast. Bioavailability was negligible whether alendronate sodium was administered with or up to [0m[1;31m2[0m[31m hours after a[0m
[31mstandardized breakfast. Concomitant administration of alendronate with coffee or orange juice reduced bioavailability by approximately [0m[1;31m60[0m[31m%.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE SODIUM label[0m


[31mCONTENT: ALENDRONATE SODIUM: indications_and_usage: [0m[1;31m1[0m[31m INDICATIONS AND USAGE BINOSTO is a bisphosphonate indicated for: Treatment of osteoporosis in postmenopausal women [0m[1;31m([0m[31m [0m[1;31m1.1[0m[31m [0m[1;31m)[0m[31m Treatment to increase [0m
[31mbone mass in men with osteoporosis [0m[1;31m([0m[31m [0m[1;31m1.2[0m[31m [0m[1;31m)[0m[31m Limitation of use: Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after [0m[1;31m3[0m[31m to [0m[1;31m5[0m[31m years [0m
[31mof use [0m[1;31m([0m[31m [0m[1;31m1.3[0m[31m [0m[1;31m)[0m[31m [0m[1;31m1.1[0m[31m Treatment of Osteoporosis in Postmenopausal Women BINOSTO effervescent tablet [0m[1;31m70[0m[31m mg is indicated for the treatment of osteoporosis in postmenopausal women. For the treatment of [0m
[31mosteoporosis, alendronate sodium increases bone mass and reduces the incidence of fractures, including those of the hip and spine [0m[1;31m([0m[31mvertebral compression fractures[0m[1;31m)[0m[31m. [0m[1;31m[[0m[31mSee Clinical Studies [0m[1;31m([0m[1;31m14.1[0m[1;31m)[0m[31m .[0m[1;31m][0m[31m [0m[1;31m1[0m[31m. [0m
[31mALENDRONATE SODIUM: indications_and_usage: [0m[1;31m2[0m[31m Treatment to Increase Bone Mass in Men With Osteoporosis BINOSTO is indicated for treatment to increase bone mass in men with osteoporosis [0m[31m . [0m[1;31m1.3[0m[31m Important[0m
[31mLimitations of Use The optimal duration of use has not been determined. The safety and effectiveness of BINOSTO for the treatment of osteoporosis are based on clinical data of four years duration. All[0m
[31mpatients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. Patients at low-risk for fracture should be considered for drug discontinuation after [0m[1;31m3[0m[31m [0m
[31mto [0m[1;31m5[0m[31m years of use. Patients who discontinue therapy should have their risk for fracture re-evaluated periodically.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE SODIUM label[0m


[31mCONTENT: ALENDRONATE SODIUM: warnings_and_cautions: [0m[1;31m5[0m[31m WARNINGS AND PRECAUTIONS Upper Gastrointestinal Adverse Reactions can occur. Instruct patients to follow dosing instructions. Discontinue if new [0m
[31mor worsening symptoms occur. [0m[1;31m([0m[31m [0m[1;31m5.1[0m[31m [0m[1;31m)[0m[31m Hypocalcemia can worsen and must be corrected prior to use. [0m[1;31m([0m[31m [0m[1;31m5.2[0m[31m [0m[1;31m)[0m[31m Severe Bone, Joint, Muscle Pain may occur. Discontinue use if severe symptoms develop. [0m[1;31m([0m[31m [0m[1;31m5.3[0m[31m [0m[1;31m)[0m[31m [0m
[31mOsteonecrosis of the Jaw has been reported. [0m[1;31m([0m[31m [0m[1;31m5.4[0m[31m [0m[1;31m)[0m[31m Atypical Femur Fractures have been reported. Patients with new thigh or groin pain should be evaluated to rule out a femoral fracture. [0m[1;31m([0m[31m [0m[1;31m5.5[0m[31m [0m[1;31m)[0m[31m [0m
[31mSodium Content: Each tablet contains [0m[1;31m603[0m[31m mg sodium, equivalent to [0m[1;31m1532[0m[31m mg NaCl. Use caution in patients on sodium restriction. [0m[1;31m([0m[31m [0m[1;31m5.7[0m[31m [0m[1;31m)[0m[31m [0m[1;31m5[0m[31m. ALENDRONATE SODIUM: warnings_and_cautions: [0m[1;31m1[0m[31m Upper [0m
[31mGastrointestinal Adverse Reactions BINOSTO, like other bisphosphonates administered orally, may cause local irritation of the upper gastrointestinal mucosa. Because of these possible irritant effects [0m
[31mand a potential for worsening of the underlying disease, caution should be used when BINOSTO is given to patients with active upper gastrointestinal problems [0m[1;31m([0m[31msuch as known Barrett's esophagus, [0m
[31mdysphagia, other esophageal diseases, gastritis, duodenitis, or ulcers[0m[1;31m)[0m[31m. Esophageal adverse experiences, such as esophagitis, esophageal ulcers and esophageal erosions, occasionally with bleeding and [0m
[31mrarely followed by esophageal stricture or perforation, have been reported in patients receiving treatment with oral bisphosphonates including alendronate sodium. In some cases these have been severe [0m
[31mand required hospitalization. ALENDRONATE SODIUM: warnings_and_cautions: Physicians should therefore be alert to any signs or symptoms signaling a possible esophageal reaction and patients should be [0m
[31minstructed to discontinue BINOSTO and seek medical attention if they develop dysphagia, odynophagia, retrosternal pain or new or worsening heartburn. The risk of severe esophageal adverse experiences [0m
[31mappears to be greater in patients who lie down after taking oral bisphosphonates including alendronate sodium, and/or who continue to take oral bisphosphonates including alendronate sodium after [0m
[31mdeveloping symptoms suggestive of esophageal irritation. Therefore, it is very important that the full dosing instructions are provided to, and understood by, the patient [0m[31m . In patients who cannot [0m
[31mcomply with dosing instructions due to mental disability, therapy with BINOSTO should be used under appropriate supervision.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE SODIUM label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ALENDRONATE SODIUM increase or decrease the risk of myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ALENDRONATE SODIUM increase or decrease the risk of[0m
[32mmyocardial infarction?[0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ALENDRONATE SODIUM increase or decrease the risk of myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ALENDRONATE SODIUM increase or decrease the risk of myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ALENDRONATE SODIUM"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does ALENDRONATE SODIUM increase or decrease the [0m
[31mrisk of myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does ALENDRONATE SODIUM increase or decrease the risk of myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether ALENDRONATE SODIUM increases or decreases the risk of myocardial infarction."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded with DO-NOT-KNOW, indicating that the FDA label for ALENDRONATE SODIUM does not specify any information regarding its effect on the risk of myocardial infarction."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"DO-NOT-KNOW"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does ALENDRONATE SODIUM increase or decrease the risk of myocardial infarction?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether ALENDRONATE SODIUM increases or decreases the risk of myocardial infarction."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded with DO-NOT-KNOW, indicating that the FDA label for ALENDRONATE SODIUM does not specify any information regarding its effect on the risk of myocardial infarction."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"DO-NOT-KNOW"[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does ALENDRONATE SODIUM increase or decrease the risk of myocardial infarction?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether ALENDRONATE SODIUM increases or decreases the risk of myocardial infarction.[0m
[1;31m2[0m[31m. FDAHandler responded with DO-NOT-KNOW, indicating that the FDA label for ALENDRONATE SODIUM does not specify any information regarding its effect on the risk of myocardial infarction.[0m
[31m        -----[0m
[31m        Final answer: DO-NOT-KNOW[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-myocardial infarction-ALENDRONATE SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m

[32mThe FDA label for ALENDRONATE SODIUM does not specify any information regarding its effect on the risk of myocardial infarction. Therefore, it is not known whether ALENDRONATE SODIUM increases or [0m
[32mdecreases the risk of myocardial infarction.[0m
